WASHINGTON — Before Scott Gottlieb was in charge of the Food and Drug Administration, he called on the agency to publicly release its rejection letters to drug manufacturers. But now as commissioner, he is stopping short of actually making that change.

“Releasing all the [complete response letters] would be administratively challenging, given the likelihood we would continue to redact certain proprietary information from these letters,” Gottlieb said Tuesday morning. He said that the agency is “evaluating whether there is a subset of complete response letters where there are especially important public health reasons to redact and release these letters.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy